Titan International Inc. (NYSE:TWI) shares moved down -9.35% in last trading session and ended the day at $2.91. TWI Gross Margin is 9.70% and its has a return on assets of -9.70%. Titan International Inc. (NYSE:TWI) quarterly performance is -62.21%.
Titan International Inc. (NYSE:TWI) announced on Friday it has filed petitions for relief from imports of off-the-road tires that are imported to the U.S. Titan International noted two petitions were filed with the U.S. International Trade Commission and the U.S. Department of Commerce. The company claimed that imports from China and India are being dumped in the U.S. market while imports from China, India and
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ended the last trading day at $16.42. Company weekly volatility is calculated as 10.05% and price to cash ratio as 9.54. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) showed a weekly performance of -19.94%.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced that Wei (William) Cao has notified the Company’s Board of Directors that, for family reasons, he will not seek renewal of his employment contract as Chief Executive Officer upon completion of his current term on February 6, 2016, but will remain as a Director of CBMG.
On 11 January, Beacon Roofing Supply, Inc. (NASDAQ:BECN) shares fell -1.43% and was closed at $37.93. BECN EPS growth in last 5 year was 10.60%. Beacon Roofing Supply, Inc. (NASDAQ:BECN) year to date (YTD) performance is -7.89%.
Investment analysts at Citigroup Inc. started coverage on shares of Beacon Roofing Supply, Inc. (NASDAQ:BECN) in a research note issued to investors on Monday, The Fly reports. The firm set a “neutral” rating on the stock.
CEL-SCI Corporation (NYSEMKT:CVM) shares advanced 0.08% in last trading session and ended the day at $0.38. CVM has a return on assets of -343.90%. CEL-SCI Corporation (NYSEMKT:CVM) quarterly performance is -47.18%.
On 5 January, CEL-SCI Corporation (NYSE MKT: CVM) announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. In the month of December it enrolled 33 patients. Total patient enrollment for the trial is now 668 as of December 31, 2015 in the world’s largest Phase 3 study in head and neck cancer.
ICICI Bank Ltd. (NYSE:IBN) caters to the Financial space. It has a net profit margin of 50.50% and weekly performance is -7.07%. On the last day of trading company shares ended up at $7.10. ICICI Bank Ltd. (NYSE:IBN) distance from 50-day simple moving average (SMA50) is -10.45%.
ICICI Bank Ltd. (NYSE:IBN) will partner FINO PayTech to foray into the payments bank space, a top official said on 7 January. “We have tied up with ICICI Bank as a partner bank for our payments bank foray. That discussion is already closed. We are now working to identify the areas where we will work together for building up avenues,” Mr. Rishi Gupta, managing director and chief executive officer of FINO PayTech, told The Hindu .
Leave a Reply